10.1 Gluconeogenesis: The Reversal Bypasses & Hexose Architecture #
While glycolysis breaks down glucose to generate rapid ATP, the metabolic architecture of animals demands alternate carbohydrate highways to handle periods of fasting, intense exercise, and oxidative stress:
1. Gluconeogenesis: Synthesizes new glucose from non-carbohydrate precursors (lactate, glycerol, glucogenic amino acids) during starvation, maintaining blood glucose above 4.0 mM to prevent hypoglycemic brain death.
2. Glycogen Turnover (Glycogenolysis and Glycogenesis): Buffers blood glucose between meals (hepatic glycogen) and fuels high-intensity muscle contraction (skeletal muscle glycogen).
3. The Pentose Phosphate Pathway (PPP): Bypasses ATP synthesis entirely to generate two vital biochemical products: NADPH (the universal reducing power for anabolic biosynthesis and antioxidant defense) and Ribose-5-Phosphate (the essential structural backbone of RNA, DNA, and nucleotide coenzymes).
Gluconeogenesis takes place predominantly in the liver (and to a lesser degree in the renal cortex). Seven of the ten glycolytic reactions sit near thermodynamic equilibrium and are shared in reverse. However, the three irreversible non-equilibrium reactions of glycolysis (Steps 1, 3, and 10) must be bypassed by four specialized gluconeogenic enzymes.
The complete pathway of gluconeogenesis, contrasting its specialized bypass enzymes against the glycolytic cascade, is depicted in Figure 10.1.

Gluconeogenesis Pathway
10.1.1 Bypass 1: Overcoming Pyruvate Kinase (Pyruvate β PEP) #
Pyruvate Kinase in glycolysis has a large negative Ξ GΒ°’ = -31.4 kJ/mol. Reversing this step requires two sequential high-energy reactions spanning two cellular compartments:
1. Pyruvate Carboxylase (Mitochondrial Matrix): Carboxylates pyruvate to Oxaloacetate (OAA), consuming 1 ATP. Utilizes the coenzyme Biotin (vitamin B7) as a CO2 carrier. Allosterically dependent on Acetyl-CoA as an obligate activator; when acetyl-CoA is abundant, it signals that the citric acid cycle is saturated and directs pyruvate into glucose synthesis.
- The Malate Shuttle: Oxaloacetate cannot cross the inner mitochondrial membrane. It is reduced to Malate by mitochondrial malate dehydrogenase, transported into the cytosol via the malate-ketoglutarate carrier, and re-oxidized back to cytosolic oxaloacetate, simultaneously transferring reducing equivalents (NADH) required for gluconeogenesis!
2. Phosphoenolpyruvate Carboxykinase (PEPCK, Cytosolic): Decarboxylates and phosphorylates oxaloacetate to form Phosphoenolpyruvate (PEP), consuming 1 GTP. The release of CO2 drives this reaction forward thermodynamically.
10.1.2 Bypass 2: Overcoming PFK-1 (F1,6BP β F6P) #
Fructose-1,6-Bisphosphatase-1 (FBPase-1) catalyzes the simple hydrolytic removal of the C-1 phosphate:
Fructose-1,6-Bisphosphate + H2O xrightleftharpoons{FBPase-1} Fructose-6-Phosphate + Pi quad (Ξ GΒ°’ = -16.3 kJ/mol)
10.1.3 Bypass 3: Overcoming Hexokinase (G6P β Glucose) #
Glucose-6-Phosphatase hydrolyzes G6P to free glucose. Crucially, this enzyme is embedded in the membrane of the endoplasmic reticulum with its active site facing the ER lumen, and is expressed only in hepatocytes and renal tubule cells! Skeletal muscle lacks this enzyme and therefore cannot export free glucose into blood.
#### Energetic Cost of Gluconeogenesis:
Synthesis of 1 mole of glucose from 2 moles of pyruvate consumes 4 ATP + 2 GTP + 2 NADH:
2Pyruvate + 4ATP + 2GTP + 2NADH + 6H2O longrightarrow Glucose + 4ADP + 2GDP + 6Pi + 2NAD+
—
10.2 Reciprocal Regulation & Fructose-2,6-Bisphosphate #
To prevent futile cycles (simultaneous glycolysis and gluconeogenesis destroying ATP as heat), both pathways are reciprocally governed by a single potent regulatory metabolite: Fructose-2,6-Bisphosphate (F2,6BP).
Fructose-6-Phosphate
β β²
(Activates) β β (Inhibits)
βββββββ΄ββββββββ΄ββββββ
βΌ β
[ PFK-1: Glycolysis ] [ FBPase-1: Gluconeogenesis ]
β² β²
β β
[ Fructose-2,6-Bisphosphate (F2,6BP) ]
β² β²
(Activated by PFK-2) (Inhibited by FBPase-2)- F2,6BP is an allosteric activator of PFK-1 (stimulates glycolysis).
- F2,6BP is an allosteric inhibitor of FBPase-1 (inhibits gluconeogenesis).
10.2.1 The Bifunctional PFK-2/FBPase-2 Master Switch #
F2,6BP is synthesized and degraded by a single polypeptide chain carrying two opposing catalytic domains:
- Fed State (High Insulin): Insulin activates protein phosphatases that dephosphorylate the bifunctional enzyme. The PFK-2 domain is active, surging F2,6BP levels, turning ON glycolysis and shutting OFF gluconeogenesis.
- Fasted State (High Glucagon): Glucagon binds hepatic GPCRs, surging cAMP and activating Protein Kinase A (PKA). PKA phosphorylates the bifunctional enzyme, inactivating PFK-2 and activating the FBPase-2 domain. F2,6BP levels plunge, shutting OFF glycolysis and liberating gluconeogenesis to maintain blood glucose!
—
10.3 Glycogen Metabolism & Reciprocal Hormonal Control #
10.3.1 Glycogenolysis (Degradation) #
1. Glycogen Phosphorylase: Uses inorganic phosphate (Pi) to cleave Ξ±(1β4) bonds phosphorolytically from non-reducing ends, releasing Glucose-1-Phosphate (G1P). Saves an ATP equivalent compared to simple hydrolysis! Requires Pyridoxal Phosphate (PLP).
2. Debranching Enzyme: When phosphorylase reaches four residues from an Ξ±(1β6) branch point:
- Transferase activity: Shifts three glucose units to a nearby non-reducing end.
- Ξ±-1,6-glucosidase activity: Hydrolyzes the remaining branched glucose residue, releasing free, unphosphorylated glucose.
3. Phosphoglucomutase: Reversibly isomerizes G1P to Glucose-6-Phosphate.
10.3.2 Glycogenesis (Synthesis) #
1. UDP-Glucose Pyrophosphorylase: Activates G1P by reacting it with UTP, forming UDP-Glucose and releasing pyrophosphate (PPi), which is immediately hydrolyzed by inorganic pyrophosphatase to drive the reaction irreversibly forward.
2. Glycogenin: An autocatalytic homodimeric enzyme that primes synthesis by attaching an initial chain of eight glucose units to a tyrosine residue on itself.
3. Glycogen Synthase: Extends linear Ξ±(1β4) chains using UDP-glucose.
4. Branching Enzyme (Amylo-Ξ±(1β4)βΞ±(1β6)-transglycosylase): Cleaves an 7-residue segment and transfers it to an internal C-6 hydroxyl, creating branch points.
The regulatory phosphorylation cascade by which glucagon stimulates glycogenolysis while halting glycogenesis is illustrated in Figure 10.2.

Regulation Of Glycogen Metabolism Glucagon
—
10.4 The Pentose Phosphate Pathway (PPP) #
Operating in the cytosol, the PPP fulfills two major cellular functions without consuming or producing ATP:
1. Synthesizes NADPH for reductive biosynthesis and cellular redox defense.
2. Generates Ribose-5-Phosphate for nucleic acid synthesis.
The two-step oxidative decarboxylation of glucose-6-phosphate yielding two molecules of NADPH is shown in Figure 10.3.

Oxidative Phase Of Pentose Phosphate Pathway
10.4.1 Phase 1: Irreversible Oxidative Decarboxylation #
1. Glucose-6-Phosphate Dehydrogenase (G6PD): Oxidizes G6P to 6-phosphoglucono-Ξ΄-lactone, reducing NADP+ to NADPH. Rate-limiting committed step.
2. Lactonase: Hydrates the lactone to 6-phosphogluconate.
3. 6-Phosphogluconate Dehydrogenase: Oxidatively decarboxylates 6-phosphogluconate, releasing CO2 and generating a second NADPH and Ribulose-5-Phosphate.
10.4.2 Phase 2: Reversible Non-Oxidative Sugar Shuffling #
When cells require NADPH more than ribose, Ribulose-5-P is converted by Transketolase (requires TPP) and Transaldolase through a series of reversible 2- and 3-carbon transfers, recycling five 6-carbon sugars from six 5-carbon pentoses back into glycolytic intermediates (F6P and GAP).
—
10.5 Curiosity Spark & Clinical Insights #
—
10.6 Key Takeaways & High-Yield Summary #
- Gluconeogenic bypasses: Pyruvate Carboxylase (biotin, mitochondrial) + PEPCK (GTP); FBPase-1; Glucose-6-Phosphatase (ER lumen, liver only).
- Master regulator: Fructose-2,6-bisphosphate activates PFK-1 and inhibits FBPase-1; levels are dictated by the phosphorylation state of the bifunctional PFK-2/FBPase-2 enzyme.
- Glycogen reciprocal control: Glucagon/PKA phosphorylates and activates Glycogen Phosphorylase while inactivating Glycogen Synthase; insulin reverses this via PP1.
- Pentose phosphate outputs: Oxidative phase produces 2 NADPH per G6P for reductive biosynthesis; non-oxidative phase interconverts pentoses with glycolytic intermediates.
—
10.7 Review & Self-Assessment Questions #
1. Why does an individual with Von Gierke disease (Type I Glycogen Storage Disease, Glucose-6-Phosphatase deficiency) suffer from profound fasting hypoglycemia accompanied by severe lactic acidosis and hyperuricemia?
- Answer: Lacking Glucose-6-Phosphatase, the liver cannot dephosphorylate G6P to export free glucose into blood, causing severe fasting hypoglycemia. Trapped G6P backs up into glycolysis, flooding pyruvate and lactate into the bloodstream (lactic acidosis). Excess G6P shunts into the pentose phosphate pathway, surging ribose-5-phosphate and purine synthesis, which are subsequently degraded into uric acid, causing gouty hyperuricemia.
2. What is the metabolic fate of lactate produced by anaerobic skeletal muscle during strenuous exertion?
- Answer: Lactate is extruded into blood and travels to the liver (the Cori Cycle). Hepatic Lactate Dehydrogenase oxidizes lactate back to pyruvate, which is converted via gluconeogenesis into glucose at the cost of 6 ATP equivalents. The newly synthesized glucose is released into blood to resupply working muscle.
—